The First FDA-Approved Targeted Treatment for KRAS-Mutant Ovarian Cancer

For the treatment of adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), the US Food and Drug Administration (FDA) has granted the avutometinib + defactinib (brand name Avumpki Fakzynja, Verastem Inc.) accelerated approval . The decision covers patients previously treated with at least one systemic therapy, including a platinum-based regimen.

The First Targeted Intervention for a Rare but Treatment-Resistant Cancer

Low-grade serous ovarian cancer (LGSOC) accounts for approximately 5% of ovarian cancers and generally affects younger women. Biologically distinct from high-grade serous carcinoma, it grows slowly but may be resistant to chemotherapy and hormonal therapy . Approximately 30-50% of patients with LGSOC have a KRAS mutation , creating a rationale for targeted therapies. Until now, however, there was no specific FDA-approved option for KRAS-mutated recurrent LGSOC .

This approval brings the first FDA-approved targeted treatment for KRAS-mutant LGSOC into clinical practice.

Scientific Basis for Approval: The Phase 2 RAMP 201 Study

The FDA approval is based on a multicenter, open-label phase 2 study involving 57 patients, RAMP 201 . Patients received the recommended combination of avutometinib (3.2 mg on two days each week) and defactinib (200 mg twice daily) in 4-week cycles.

Key Findings:

• Response rate (ORR): 44%

• Duration of response (DOR): 3.3 to 31.1 months

• The combination had previously received Breakthrough Therapy and Orphan Drug designations.

These findings demonstrated a promising activity profile in this rare patient group.

How Do Avutometinib and Defactinib Work?

Avutometinib , a MEK inhibitor, inhibits MEK1/2 enzymes in the RAS/RAF/MEK/ERK pathway, stopping tumor-cell proliferation and triggering programmed cell death. This pathway is overactive because of KRAS mutations, making MEK inhibition potentially effective in KRAS-mutant tumors.

Defactinib , a FAK inhibitor, reduces cell movement, invasion, and immunosuppressive effects in the tumor microenvironment through focal adhesion kinase (FAK). It limits tumor-cell spread and works synergistically with MEK inhibitors to improve treatment response.

Common Adverse Reactions

Reactions reported at a frequency of at least 25% included:

• Increased creatine phosphokinase

• Fatigue, nausea, diarrhea

• Elevated liver enzymes (AST, ALT)

• Rash, musculoskeletal pain

• Visual disturbances, acneiform dermatitis, stomatitis

• Decreased white blood cell and platelet counts

Although most adverse reactions were manageable, careful monitoring during treatment is recommended.

Conclusion

Avutometinib plus defactinib offers a long-awaited option for patients with recurrent KRAS-mutant LGSOC and should now be viewed as a new standard.

This development may mark the beginning of targeted therapy for KRAS-mutant low-grade serous ovarian cancer. As genetic profiling becomes increasingly important, approvals for specific molecular subgroups offer new hope to clinicians and patients.